Table 4.

Association between FGFR2 rs1219648 and clinicopathological features of 328 breast cancer patients

Parameters	FGFR2 rs1219648
	AA	AG	GG	AG+GG
Age (years)
≤50/>50	39/128	35/92	14/20	49/112
OR (95% CI)	1.00	0.80 (0.47–1.36)	0.44 (0.20–0.94)	0.70 (0.43–1.12)
R2 value		2.30E-3	2.31E-2	6.40E-3
p-value		0.410	0.032	0.148
Tumor size (cm)
≤2/>2	42/125	20/107	10/24	30/131
OR (95% CI)	1.00	1.80 (1.00–3.25)	0.81 (0.37–1.82)	1.47 (0.87–2.49)
R2 value		1.30E-2	1.29E-3	6.24E-3
p-value		0.05	0.61	0.154
Stage
I+II/III+IV	129/38	84/43	21/13	105/56
OR (95% CI)	1.00	1.74 (1.04–2.91)	2.10 (0.96–4.59)	1.82 (1.11–2.94)
R2 value		1.51E-2	1.77E-2	1.77E-2
p value		0.035*	0.059	0.016*
Grade
I+II/III	62/105	70/57	6/28	76/85
OR (95% CI)	1.00	0.48 (0.30–0.77)	2.76 (1.08–7.03)	0.66 (0.43–1.03)
R2 value		3.20E-2	2.37E-2	1.04E-2
p-value		0.002*	0.029*	0.065
Lymph node invasion
No/Yes	87/80	58/69	12/22	70/91
OR (95% CI)	1.00	1.29 (0.82–2.06)	1.99 (0.93–4.29)	1.41 (0.92–2.18)
R2 value		4.10E-3	1.59E-2	7.40E-3
p-value		0.275	0.074	0.118
ER status
Negative/positive	74/93	55/72	17/17	72/89
OR (95% CI)	1.00	1.04 (0.65–1.66)	0.80 (0.38–1.67)	0.98 (0.64–1.52)
R2 value		1.00E-4	1.85E-3	1.60E-5
p-value		0.864	0.544	0.941
PR status
Negative/positive	65/102	58/69	16/18	74/87
OR (95% CI)	1.00	0.76 (0.48–1.21)	0.72 (0.34–1.51)	0.75 (0.48–1.16)
R2 value		4.62E-3	3.84E-3	5.04E-3
p-value		0.245	0.378	0.197
HER2 status
Negative/positive	118/49	94/33	30/4	124/37
OR (95% CI)	1.00	0.85 (0.50–1.42)	0.32 (0.11–0.96)	0.72 (0.44–1.18)
R2 value		1.37E-3	2.25E-2	5.18E-3
p-value		0.525	0.034*	0.190

Note:

^*p<0.05, as compared to AA genotype.